Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
about
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostaKRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.Selumetinib for the treatment of non-small cell lung cancer.Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.Selumetinib in the treatment of non-small-cell lung cancer.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.Functional exploration of colorectal cancer genomes using Drosophila.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trialsCorrelation between MEK signature and Ras gene alteration in advanced gastric cancer.MEK inhibitors under development for treatment of non-small-cell lung cancer.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
P2860
Q37477372-0728B4B8-FFF1-4E12-BF27-0598C8DBEBDAQ37709450-72B13801-0943-42F8-A2C4-8E113C8BB2A7Q37743107-54E8428D-1CA0-45B8-8290-B0F4CD2DCAF1Q38663069-B072B922-BAF7-4D7D-AC40-5F5134935181Q38792704-42090C28-8975-4279-9F58-115A28FC33D9Q38836927-8B2CFBC9-6228-44A2-8DD7-881B00423BC7Q38899873-75C82F77-2761-4D9B-BF01-FED0A8A2E09CQ39045958-C853D65A-1EA1-4F28-8F10-F176FA0C9939Q39145987-48120BC1-27B3-44F3-AC92-0133150D441BQ39220897-18FAF270-12B4-46F9-BCCF-D5D2A1DF74BCQ39538184-AA2643BA-57B2-440E-85FF-86DFEC4143E9Q42332672-F4704D63-52B2-48B6-84B6-42BDA821BB9AQ42363767-D2AD8175-07BA-4F90-BBB0-7FCAEA96CD37Q42700668-0688945E-8E2A-40A1-9C79-CFD0B81EEC31Q47145152-2BA54EDB-C980-4044-BD99-FFEE82DB2967Q47318847-6987F296-C6CD-42DE-9E82-A0B5131A21DBQ47671139-8A042A02-5348-4E08-9FC2-7ABBF8845053Q49787333-C541260F-08CC-4C98-A23F-256A97F5EEECQ49887897-1E0E6DCF-66F9-41E5-9602-EA33A2ABF7B5Q50345931-D9358691-9DE8-41EE-8FFE-481F81D324D7Q55259943-10BE58A4-390C-49B8-B36E-D37EAC946979Q55339149-4B4EF36D-42E5-44F6-9F23-AB7D8025BDB0
P2860
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Selumetinib with and without e ...... ced nonsmall-cell lung cancer.
@ast
Selumetinib with and without e ...... ced nonsmall-cell lung cancer.
@en
type
label
Selumetinib with and without e ...... ced nonsmall-cell lung cancer.
@ast
Selumetinib with and without e ...... ced nonsmall-cell lung cancer.
@en
prefLabel
Selumetinib with and without e ...... ced nonsmall-cell lung cancer.
@ast
Selumetinib with and without e ...... ced nonsmall-cell lung cancer.
@en
P2093
P2860
P50
P356
P1433
P1476
Selumetinib with and without e ...... nced nonsmall-cell lung cancer
@en
P2093
C A Carter
C Brzezniak
J B Trepel
P2860
P304
P356
10.1093/ANNONC/MDW008
P577
2016-01-22T00:00:00Z